Mektovi Dosage
Generic name: BINIMETINIB 15mg
Dosage form: tablet, film coated
Drug class: Multikinase inhibitors
Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.
Patient Selection
BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma
Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating MEKTOVI. Do not take a missed dose of MEKTOVI within 6 hours of the next dose of MEKTOVI.
Do not take an additional dose if vomiting occurs after MEKTOVI administration but continue with the next scheduled dose.
Dosage Modifications for Adverse Reactions
If encorafenib is permanently discontinued, discontinue MEKTOVI.
Dose reductions for adverse reactions associated with MEKTOVI are presented in Table 1.
Action | Recommended Dose |
---|---|
First Dose Reduction |
30 mg orally twice daily |
Subsequent Modification |
Permanently discontinue if unable to tolerate MEKTOVI 30 mg orally twice daily |
Dosage modifications for adverse reactions associated with MEKTOVI are presented in Table 2.
Severity of Adverse Reaction* | Dose Modification for MEKTOVI |
---|---|
|
|
Cardiomyopathy |
|
|
Withhold MEKTOVI for up to 4 weeks, evaluate LVEF every 2 weeks.
If the LVEF does not recover within 4 weeks permanently discontinue MEKTOVI. |
|
Permanently discontinue MEKTOVI. |
Venous Thromboembolism |
|
|
Withhold MEKTOVI.
|
|
Permanently discontinue MEKTOVI. |
Serous Retinopathy |
|
|
Withhold MEKTOVI for up to 10 days.
|
Retinal Vein Occlusion (RVO) |
|
|
Permanently discontinue MEKTOVI. |
Uveitis |
|
|
If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold MEKTOVI for up to 6 weeks.
|
|
Permanently discontinue MEKTOVI. |
Interstitial Lung Disease |
|
|
Withhold MEKTOVI for up to 4 weeks.
|
|
Permanently discontinue MEKTOVI. |
Hepatotoxicity |
|
|
Maintain MEKTOVI dose.
|
|
|
Rhabdomyolysis or Creatine Phosphokinase (CPK) elevations |
|
|
Withhold MEKTOVI dose for up to 4 weeks.
|
Dermatologic [other than palmar plantar erythrodysesthesia syndrome (PPES)] |
|
|
If no improvement within 2 weeks, withhold MEKTOVI until Grade 0-1. Resume at same dose if first occurrence or reduce dose if recurrent. |
|
Withhold MEKTOVI until Grade 0-1. Resume at same dose if first occurrence or reduce dose if recurrent. |
|
Permanently discontinue MEKTOVI. |
Other Adverse Reactions (including Hemorrhage)† |
|
|
Withhold MEKTOVI for up to 4 weeks.
|
|
Permanently discontinue MEKTOVI, or
|
|
Consider permanently discontinuing MEKTOVI. |
|
Permanently discontinue MEKTOVI. |
Refer to the encorafenib prescribing information for dose modifications for adverse reactions associated with encorafenib.
Dosage Modifications for Moderate or Severe Hepatic Impairment
For patients with moderate (total bilirubin greater than 1.5 and less than or equal to 3 × ULN and any AST) or severe (total bilirubin levels greater than 3 × ULN and any AST) hepatic impairment, the recommended dosage is 30 mg orally taken twice daily.
Frequently asked questions
More about Mektovi (binimetinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.